Genentech wins FDA OK for at-home combo of 2 marquee cancer drugs

Genentech Inc. won regulatory approval Monday of a breast cancer treatment that combines Herceptin and Perjeta with an enzyme and can be administered at home. The drug, branded as Phesgo, is the first time South San Francisco-based Genentech has combined two monoclonal antibodies that can be administered by a single injection just under the skin in combination with intravenous chemotherapy. With the enzyme hyaluronidase, it was approved for treatment of early and metastatic HER2-positive breast…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news